SunTrust analyst Joon Lee raised his price target for Catalyst Pharmaceuticals to $11 from $9 and recommends buying the stock on today's post-earnings weakness. The company reported a "strong" quarter with Firdapse sales topping expectations, Lee tells investors in a research note. The analyst is "less bullish" into the Phase 3 congenital myasthenic syndromes data in the second half of 2019, but believes the readout could be a "clearing event" for the Phase 2b anti-MuSK antibody positive myasthenia gravis trial data in the first half of 2020. He's "more bullish" on the latter and keeps a Buy rating on Catalyst Pharmaceuticals.